When was Visiopharm founded?

Visiopharm was founded in 2001 and raised its 1st funding round 1 year after it was founded.

Where is Visiopharm located?

Visiopharm is headquartered in Horsholm, Denmark.

Which legal entities is Visiopharm associated with?

Visiopharm is associated with Visiopharm A/s.

How many employees does Visiopharm have?

As of Jul 31, 2026, the latest employee count at Visiopharm is 90.

Is Visiopharm a funded company?

Visiopharm is a funded company, having raised a total of $26.3M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 12, 2002.

How much is Visiopharm worth?

The last known valuation of Visiopharm was $***** as of Jul 01, 2020.

When was the latest funding round of Visiopharm?

Visiopharm's latest funding was a $***** Series B round on Jul 01, 2020, with participation from 5 investors.

Where does Visiopharm rank among its competitors?

Visiopharm ranks 8th amongst 291 active competitors, of which 86 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Techcyte, which secured $15M in Apr, 2026.

Who are the top competitors of Visiopharm?

Visiopharm's top competitors include PathAI, Deciphex and Aiforia. Among them, Techcyte secured the most recent funding round in April, 2026.

Visiopharm - 2026 Company Profile, Team, Funding, Competitors & Financials

Visiopharm is an acquired company based in Horsholm (Denmark), founded in 2001 by Johan Dore and Michael Grunkin. It operates as a Developer of a SaaS and AI-based digital pathology solutions for image analysis and workflow standardization. Visiopharm has raised $26.3M in funding from Vaekstfonden and BankInvest, with last known valuation of $*****. The company has 291 active competitors, including 86 funded and 16 that have exited. Its top competitors include companies like PathAI, Deciphex and Aiforia.

Company Details

Visiopharm is a developer of AI-based digital pathology solutions for image analysis and workflow standardization. The company offers three software solutions for clinicians and researchers. BioTopix is digital imaging software for analyzing pathology slides that have been tailored for drug researchers to enable biomarker discovery and quantification. Oncotopix uses a combination of virtual double staining and multiplexed biomarker tissue arrays for cancer diagnostics. Stereotopix is used to quantitatively analyze changes in tissue structure using Tissuealign. It also offers AI algorithms and a deep learning platform for better imaging solutions for diagnostic approaches and decision support.

Website: visiopharm.com
Social

Key Metrics

Founded Year

2001

Location

Horsholm, Denmark

Stage

Acquired

Total Funding

$26.3M in 7 rounds

Latest Funding Round

Series B, Jul 01, 2020, $*****

Last Known Valuation

$***** as on Jul 01, 2020

Investors

Vaekstfonden & 5 more

Ranked

8^th among 291 active competitors

Employee Count

90 as on Jul 31, 2026

Similar Companies

PathAI & 327 more

Exit Details

Acquired by Grundium (May 21, 2026)

View Visiopharm's full profile

Visiopharm is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Visiopharm A/s CIN: 26186676 , Denmark, Active	Jul 08, 2001	-	86 (As on Dec 31, 2021)

Visiopharm got acquired by Grundium on May 21, 2026.

Click here to take a look at Visiopharm's acquisition in detail

Visiopharm has raised a total funding of $26.3M over 7 rounds. Its first funding round was on Nov 12, 2002. Its latest funding round was a Series B round on Jul 01, 2020 for $*****. 5 investors participated in its latest round. Visiopharm has 6 institutional investors.

Here is the list of recent funding rounds of Visiopharm:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 01, 2020	2015100	Series B	7533615	9056215	5836657	4984341
Jul 06, 2018	7579074	Series B	9320890	4275406	6794990	ATP & 1 more
Nov 29, 2016	1004718	Series A	3654692	9340063	4147051	8013938

Access funding benchmarks and valuations. Sign up today!

View details of Visiopharm's funding rounds and investors

The founders of Visiopharm are Johan Dore and Michael Grunkin.

Here are the details of Visiopharm's key team members:

Johan Dore: Co-Founder & CTO of Visiopharm. They serve on the board of 1 company.
Michael Grunkin: Co-Founder & CEO of Visiopharm. They serve on the board of 1 company.

Visiopharm's Board of Directors

Visiopharm's board has 6 active members. Martin Bonde is part of team and Claus Henrik Nielsen, Patrik Olof Dahlén, Henrik Stender, Thomas Weilby Knudsen and Susanne Høiberg are independent board members.

Here is the list of Visiopharm's board of directors:

Name	Type	Representing	Status	Duration
Martin Bonde	Team	-	Current	8y 2m
vphnslp	Team	-	Past	5y 3m
zsumxeq	Team	-	Past	1y 6m
Claus Henrik Nielsen	Independent board member	-	Current	8y 1m
y{vxpoj	Independent board member	-	Current	3y 5m
acjajbg	Independent board member	-	Current	3y 2m
kcxqpxk	Independent board member	-	Current	3y 4m
dotrnez	Independent board member	-	Current	1y 1m

View details of Visiopharm's Founder profiles and Board Members

Visiopharm's employee count trend

Visiopharm has 90 employees as of Jul 26. Here is Visiopharm's employee count trend over the years:

Uncover Visiopharm's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Visiopharm include PathAI, Deciphex and Aiforia. Here is the list of Top 10 competitors of Visiopharm, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	PathAI 2016, Boston (United States), Series C	Provider of digital pathology image management system for clinical labs	$255M	General Catalyst, General Atlantic & 22 others	71/100
2nd	Deciphex 2017, Dublin (Ireland), Series C	Network of pathologists providing digital diagnostic services for medical testing	$56.6M	Seroba Life Sciences, Molten Ventures & 13 others	65/100
3rd	Aiforia 2014, Helsinki (Finland), Public	Provider of an AI and cloud-based, deep learning image analysis platform in all therapy areas	$23M	Ascend Capital Partners, Businessfinland & 8 others	64/100
4th	Aignostics 2018, Berlin (Germany), Series B	Developer of artificial intelligence software for biomedical image analysis applications	$53.9M	Wellington Partners Venture Capital, Boehringer Ingelheim Venture Fund ... & 9 others	64/100
5th	Nucle AI 2017, Chicago (United States), Series B	AI-assisted platform for image analysis	$60M	Vertex Ventures Israel, Sanofi Ventures & 9 others	62/100
6th	Techcyte 2014, Orem (United States), Series B	Artificial intelligence (AI) based image analysis platform for pathologists	$50.4M	ARUP Laboratories, Zoetis & 2 others	62/100
7th	Onc.ai 2020, San Carlos (United States), Series A	AI-based cancer treatment and diagnosis platform for healthcare providers	$31M	Accomplice, MassMutual & 12 others	61/100
8th	Visiopharm 2001, Horsholm (Denmark), Acquired	Developer of a SaaS and AI-based digital pathology solutions for image analysis and workflow standardization	$26.3M	ATP, Northcap Partners & 4 others	60/100
9th	PAIGE 2018, New York City (United States), Acquired	Developer of AI applications and foundation models for cancer diagnostics	$241M	Goldman Sachs, Casdin Capital & 9 others	59/100
10th	Proscia 2014, Philadelphia (United States), Series C	Provider of an AI and cloud-based digital pathology solution for cancer diagnosis	$129M	Triangle Peak Partners, TEDCO & 22 others	59/100